|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel
Members, : Tailoring therapies-improving the management of early
breast cancer: St Gallen international expert consensus on the
primary therapy of early breast cancer 2015. Ann Oncol.
26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mehnati P and Tirtash MJ: Comparative
efficacy of four imaging instruments for breast cancer screening.
Asian Pac J Cancer Prev. 16:6177–6186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang SN, Li FJ, Liao YH, Chen YS, Shen WC
and Huang TC: Identification of breast cancer using integrated
information from MRI and mammography. PLoS One. 10:e01284042015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peng J, Sengupta S and Jordan VC:
Potential of selective estrogen receptor modulators as treatments
and preventives of breast cancer. Anticancer Agents Med Chem.
9:481–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reeder JG and Vogel VG: Breast cancer
prevention. Cancer Treat Res. 141:149–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liscovitch M and Lavie Y: Cancer multidrug
resistance: A review of recent drug discovery research. IDrugs.
5:349–355. 2002.PubMed/NCBI
|
|
10
|
De Lena M, Brambilla C, Morabito A and
Bonadonna G: Adriamycin plus vincristine compared to and combined
with cyclophosphamide, methotrexate, and 5-fluorouracil for
advanced breast cancer. Cancer. 35:1108–1115. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bates D and Eastman A: Microtubule
destabilising agents: Far more than just antimitotic anticancer
drugs. Br J Clin Pharmacol. 83:255–268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mansoori B, Mohammadi A, Davudian S,
Shirjang S and Baradaran B: The different mechanisms of cancer drug
resistance: A brief review. Adv Pharm Bull. 7:339–348. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu F, Song D, Yan Y, Huang C, Shen C, Lan
J, Chen Y, Liu A, Wu Q, Sun L, et al: IL-6 regulates autophagy and
chemotherapy resistance by promoting BECN1 phosphorylation. Nat
Commun. 12:36512021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Novototskaya-Vlasova KA, Neznanov NS,
Molodtsov I, Hall BM, Commane M, Gleiberman AS, Murray J, Haber M,
Norris MD, Leonova KI and Gudkov AV: Inflammatory response to
retrotransposons drives tumor drug resistance that can be prevented
by reverse transcriptase inhibitors. Proc Natl Acad Sci USA.
119:e22131461192022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duncavage EJ, Bagg A, Hasserjian RP,
DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L,
Vannucchi AM, Patel KP, et al: Genomic profiling for clinical
decision making in myeloid neoplasms and acute leukemia. Blood.
140:2228–2247. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marasco LE and Kornblihtt AR: The
physiology of alternative splicing. Nat Rev Mol Cell Biol.
24:242–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lv Y, Zhang W, Zhao J, Sun B, Qi Y, Ji H,
Chen C, Zhang J, Sheng J, Wang T, et al: SRSF1 inhibits autophagy
through regulating Bcl-x splicing and interacting with PIK3C3 in
lung cancer. Signal Transduct Target Ther. 6:1082021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kitamura K and Nimura K: Regulation of RNA
splicing: Aberrant splicing regulation and therapeutic targets in
cancer. Cells. 10:9232021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Read A and Natrajan R: Splicing
dysregulation as a driver of breast cancer. Endocr Relat Cancer.
25:R467–R478. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Hu Z, Shi H, Wang C, Lei J and Cheng
Y: Inhibition of VEGFA increases the sensitivity of ovarian cancer
cells to chemotherapy by suppressing VEGFA-mediated autophagy. Onco
Targets Ther. 13:8161–8171. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang BW, Jiang Y, Yao ZL, Chen PS, Yu B
and Wang SN: Aucubin protects chondrocytes against IL-1β-induced
apoptosis in vitro and inhibits osteoarthritis in mice model. Drug
Des Devel Ther. 13:3529–3538. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wooster R and Weber BL: Breast and ovarian
cancer. N Engl J Med. 348:2339–2347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kavallaris M, Tait AS, Walsh BJ, He L,
Horwitz SB, Norris MD and Haber M: Multiple microtubule alterations
are associated with vinca alkaloid resistance in human leukemia
cells. Cancer Res. 61:5803–5809. 2001.PubMed/NCBI
|
|
29
|
Sirotnak FM, Danenberg KD, Chen J, Fritz F
and Danenberg PV: Markedly decreased binding of vincristine to
tubulin in vinca alkaloid-resistant Chinese hamster cells is
associated with selective overexpression of alpha and beta tubulin
isoforms. Biochem Biophys Res Commun. 269:21–24. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verrills NM, Walsh BJ, Cobon GS, Hains PG
and Kavallaris M: Proteome analysis of vinca alkaloid response and
resistance in acute lymphoblastic leukemia reveals novel
cytoskeletal alterations. J Biol Chem. 278:45082–45093. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stow MW and Warr JR: Reduced influx is a
factor in accounting for reduced vincristine accumulation in
certain verapamil-hypersensitive multidrug-resistant CHO cell
lines. FEBS Lett. 320:87–91. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yao D, Ding S, Burchell B, Wolf CR and
Friedberg T: Detoxication of vinca alkaloids by human P450
CYP3A4-mediated metabolism: Implications for the development of
drug resistance. J Pharmacol Exp Ther. 294:387–395. 2000.PubMed/NCBI
|
|
34
|
Kontos CK, Christodoulou MI and Scorilas
A: Apoptosis-related BCL2-family members: Key players in
chemotherapy. Anticancer Agents Med Chem. 14:353–374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Urfali-Mamatoglu C, Kazan HH and Gündüz U:
Dual function of programmed cell death 10 (PDCD10) in drug
resistance. Biomed Pharmacother. 101:129–136. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ferrara N: Vascular endothelial growth
factor: Basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Delforce SJ, Lumbers ER, Morosin SK, Wang
Y and Pringle KG: The Angiotensin II type 1 receptor mediates the
effects of low oxygen on early placental angiogenesis. Placenta.
75:54–61. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takahashi T, Yamaguchi S, Chida K and
Shibuya M: A single autophosphorylation site on KDR/Flk-1 is
essential for VEGF-A-dependent activation of PLC-gamma and DNA
synthesis in vascular endothelial cells. EMBO J. 20:2768–2778.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
van Hinsbergh VW and Koolwijk P:
Endothelial sprouting and angiogenesis: Matrix metalloproteinases
in the lead. Cardiovasc Res. 78:203–212. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garlanda C, Dinarello CA and Mantovani A:
The interleukin-1 family: Back to the future. Immunity.
39:1003–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brough D, Tyrrell PJ and Allan SM:
Regulation of interleukin-1 in acute brain injury. Trends Pharmacol
Sci. 32:617–622. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baroja-Mazo A, Martín-Sánchez F, Gomez AI,
Martínez CM, Amores-Iniesta J, Compan V, Barberà-Cremades M, Yagüe
J, Ruiz-Ortiz E, Antón J, et al: The NLRP3 inflammasome is released
as a particulate danger signal that amplifies the inflammatory
response. Nat Immunol. 15:738–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dinarello CA: Interleukin-1. Cytokine
Growth Factor Rev. 8:253–265. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tulotta C and Ottewell P: The role of
IL-1B in breast cancer bone metastasis. Endocr Relat Cancer.
25:R421–R434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jang K, Kim M, Gilbert CA, Simpkins F,
Ince TA and Slingerland JM: VEGFA activates an epigenetic pathway
upregulating ovarian cancer-initiating cells. EMBO Mol Med.
9:304–318. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang W, Ren F, Wu Q, Jiang D, Li H and Shi
H: MicroRNA-497 suppresses angiogenesis by targeting vascular
endothelial growth factor A through the PI3K/AKT and MAPK/ERK
pathways in ovarian cancer. Oncol Rep. 32:2127–2133. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y,
Li PY, Wang M, Lin JS and He XX: MiR-497 suppresses angiogenesis
and metastasis of hepatocellular carcinoma by inhibiting VEGFA and
AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zeng FC, Zeng MQ, Huang L, Li YL, Gao BM,
Chen JJ, Xue RZ and Tang ZY: Downregulation of VEGFA inhibits
proliferation, promotes apoptosis, and suppresses migration and
invasion of renal clear cell carcinoma. Onco Targets Ther.
9:2131–2141. 2016.PubMed/NCBI
|
|
50
|
Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G,
Hou Y and Jiang P: MicroRNA-140-5p inhibits the progression of
colorectal cancer by targeting VEGFA. Cell Physiol Biochem.
37:1123–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Adams J, Carder PJ, Downey S, Forbes MA,
MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ,
et al: Vascular endothelial growth factor (VEGF) in breast cancer:
Comparison of plasma, serum, and tissue VEGF and microvessel
density and effects of tamoxifen. Cancer Res. 60:2898–2905.
2000.PubMed/NCBI
|
|
52
|
Lawicki S, Będkowska GE, Gacuta-Szumarska
E and Szmitkowski M: The plasma concentration of VEGF, HE4 and
CA125 as a new biomarkers panel in different stages and sub-types
of epithelial ovarian tumors. J Ovarian Res. 6:452013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fleming ND, Coleman RL, Tung C, Westin SN,
Hu W, Sun Y, Bhosale P, Munsell MF and Sood AK: Phase II trial of
bevacizumab with dose-dense paclitaxel as first-line treatment in
patients with advanced ovarian cancer. Gynecol Oncol. 147:41–46.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fahmy K, Gonzalez A, Arafa M, Peixoto P,
Bellahcène A, Turtoi A, Delvenne P, Thiry M, Castronovo V and
Peulen O: Myoferlin plays a key role in VEGFA secretion and impacts
tumor-associated angiogenesis in human pancreas cancer. Int J
Cancer. 138:652–663. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bent R, Moll L, Grabbe S and Bros M:
Interleukin-1 beta-A friend or foe in malignancies? Int J Mol Sci.
19:21552018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Apte RN, Dotan S, Elkabets M, White MR,
Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y and Voronov E: The
involvement of IL-1 in tumorigenesis, tumor invasiveness,
metastasis and tumor-host interactions. Cancer Metastasis Rev.
25:387–408. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Saijo Y, Tanaka M, Miki M, Usui K, Suzuki
T, Maemondo M, Hong X, Tazawa R, Kikuchi T, Matsushima K and Nukiwa
T: Proinflammatory cytokine IL-1 beta promotes tumor growth of
Lewis lung carcinoma by induction of angiogenic factors: In vivo
analysis of tumor-stromal interaction. J Immunol. 169:469–475.
2002. View Article : Google Scholar : PubMed/NCBI
|
